ArticleJournal of market access & health policy2017
Key drivers for market penetration of biosimilars in Europe.
Article in Journal of market access & health policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence.International journal of clinical pharmacy · 2025Pooled it
- Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Pooled it
- Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review.Journal of managed care & specialty pharmacy · 2019Pooled it
- Application of Actor Network Theory to Evaluate Supply and Demand Strategies Used to Encourage International Biosimilar Uptake.Pharmaceutical medicine · 2026Review
- Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?International journal of clinical pharmacy · 2026Article
- Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.Clinical pharmacology and therapeutics · 2026Article
- Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan.Journal of pharmaceutical policy and practice · 2026Article
- Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability.Frontiers in pharmacology · 2025Article
- Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians.PharmacoEconomics - open · 2024Article
- Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.Global health research and policy · 2024Article
- Proposal of a Knowledge Management Model for Complex Systems: Case of the Supervision and Control Subsystem of the Colombian Health System.Journal of market access & health policy · 2024Article
- The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- Article
- What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France.Applied health economics and health policy · 2023Article
- The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis.Health research policy and systems · 2023Article
- Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.